Needham & Company Reaffirms Buy Rating for Boston Scientific

Research firm maintains price target of $97 on medical device maker's stock

Mar. 30, 2026 at 12:08pm

Got story updates? Submit your updates here. ›

Needham & Company LLC reiterated its 'buy' rating and $97 price target on shares of Boston Scientific Corporation (NYSE:BSX), a leading medical device manufacturer. The research firm cited the company's strong product pipeline and market position in its continued recommendation to investors.

Why it matters

Boston Scientific is a major player in the medical device industry, with a diverse portfolio of cardiovascular, digestive, and other products used in minimally invasive procedures. Needham's positive outlook on the stock signals confidence in the company's ability to maintain its market leadership and drive future growth.

The details

In its research note, Needham cited Boston Scientific's robust product pipeline and market positioning as key factors supporting its 'buy' rating. The firm believes the company is well-positioned to capitalize on trends in the medical technology sector, including the continued shift towards less invasive surgical techniques.

  • Needham & Company issued its research note on Monday, March 30, 2026.

The players

Boston Scientific

A leading global medical device company that develops, manufactures, and markets a broad range of products used in less-invasive medical procedures.

Needham & Company LLC

A full-service investment bank that provides research, sales, trading, and investment banking services to institutional and individual investors.

Got photos? Submit your photos here. ›

What they’re saying

“Needham & Company LLC reissued a "buy" rating and set a $97.00 price target on shares of Boston Scientific in a research report on Monday.”

— Needham & Company LLC, Research Firm

What’s next

Investors will be closely watching Boston Scientific's upcoming earnings report and any further updates from the company and industry analysts on the medical device maker's performance and outlook.

The takeaway

Needham & Company's continued 'buy' rating and price target for Boston Scientific suggests the research firm sees the company maintaining its strong position in the medical device market and delivering solid financial results for investors.